Core Viewpoint - Vincerx Pharma, Inc. is urging stockholders to vote for the Dissolution Proposal, which could lead to potential distributions of $0.04 to $0.08 per share if approved, while delays could reduce or eliminate these distributions [1][2][3]. Group 1: Dissolution Proposal - The Special Meeting to consider the Dissolution Proposal has been adjourned to July 16, 2025, and will be held via live audio webcast [1]. - Vincerx estimates that, upon approval of the Dissolution Proposal, stockholders could receive between $0.04 to $0.08 per share of outstanding common stock [2][7]. - The board of directors unanimously recommends that stockholders vote for the Dissolution Proposal, emphasizing that every vote is crucial and delays could increase costs, reducing potential distributions [3][5]. Group 2: Financial Implications - Continued delays in approving the Dissolution Proposal will lead to ongoing operating costs, which may diminish or eliminate funds available for distribution to stockholders [2][7]. - Timely approval of the Dissolution Proposal may allow U.S. stockholders to recognize capital losses for tax purposes if they receive less than their tax basis in their shares [7]. Group 3: Voting Process - Stockholders are encouraged to vote immediately, with instructions provided for voting by phone or internet [4][7].